Newsroom

Portola Pharmaceuticals Announces Senior Management and Board Changes PDF 50KB

Portola Pharmaceuticals Announces Late-Breaker Presentation on Betrixaban PDF 71KB

Portola Pharmaceuticals Announces Promotions of Senior Management Team PDF 30KB

Portola Pharmaceuticals Announces Two Oral Presentations on Elinogrel at European Society of Cardiology Congress 2009 PDF 26KB

Portola Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress PDF 34KB

Merck & Co., Inc. and Portola Enter Worldwide License Agreement to Develop and Commercialize Betrixaban, a Novel Investigational Oral Anticoagulant for Cardiovascular Disease PDF 32KB

Portola announced as one of FierceBiotech's 2009 Fierce 15 PDF 96KB

Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel PDF 28KB

Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention PDF 26KB

Portola Data on its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting PDF 24KB

Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix®) Non-Responders PDF 82KB

Portola Announces Data Presentations Relevant to its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008 PDF 23KB

Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation PDF 65KB

Portola Completes $60 Million Financing to Advance its Therapeutic Programs PDF 20KB

Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Development PDF 144KB

Portola Initiates Phase II Clinical Program in Heart Attack Patients with its Novel Antiplatelet Agent, PRT060128 PDF 44KB

Portola Pharmaceuticals, Inc. Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor PDF 76KB

Portola Pharmaceuticals, Inc. Announces Positive Phase II EXPERT Results PDF 76KB

Portola Pharmaceuticals, Inc. Announces Completion of $70 Million Series C Financing PDF 12KB

Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery PDF 48KB